A study of an experimental drug to prevent HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a cisgender woman (assigned female at birth)
- You must be HIV-negative (tested negative for HIV-1 and HIV-2)
- You have had vaginal sex with a male partner at least twice in the last 3 months
- You weigh at least 35 kg (about 77 pounds)
- You have not used certain long-acting HIV prevention drugs (like cabotegravir or lenacapavir) ever
- You have not received an HIV vaccine or HIV antibodies in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
This study tests whether a new medicine called MK-8527, combined with the antibiotic rifampin, can safely treat latent tuberculosis infection (a dormant TB infection that shows no symptoms). You may qualify if you have untreated latent TB but feel well otherwise.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.